Erectile Dysfunction - Conclusions

Erectile dysfunction is a highly prevalent disorder which is frequently associated with loss of selfesteem and a reduced quality of life. The condition affects not only the individual, but also their partner. As it is strongly age-related, the incidence of erectile dysfunction is likely to increase with the ‘graying’ of society.

Rapid advances have recently been made in our understanding of the mechanisms of penile erection and the pathophysiology of erectile dysfunction. These have now been translated into a number of safe and effective treatment possibilities that offer a practical solution to the large numbers of men and their partners who are suffering as a result of this disorder. These therapies need to be employed in a goal-oriented manner, with careful attention being paid to patient preferences.

Unfortunately, many health-care practitioners are still too embarrassed to discuss sexual problems frankly and, as a consequence, avoid raising these issues with their patients. The onus now falls on those who care for the many patients with erectile dysfunction to initiate the discussion and to inform and instruct them and their partners as to the cause of their problem, and the safest and most effective means by which natural erectile function may be restored and sexual activity resumed.

Bibliography

  • Amin Z, Patel U, Friedman EP, et al. Colour Doppler and duplex ultrasound assessment of Peyronie’s disease in impotent men. Br J Radiol 1993;66:398–402
  • Anders EK, Bradley WE, Krane RJ. Nocturnal penile rigidity measured by the snap-gauge band. J Urol 1983;129:964–6
  • Andersson KE, Holmquist F, Wagner G. Pharmacology of drugs used for treatment of erectile dysfunction and priapism. Int J Impot Res 1991;3:155–72
  • Andersson KE, Wagner G. Physiology of penile erection. Physiol Rev1995;75:191–236
  • Arruda-Olson, Mahoney DW, Nehra A, et al. Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease: a randomized crossover trial. J Am Med Assoc 2002;287:719–25
  • Bancroft J, Wu FC. Changes in erectile responsiveness during androgen replacement therapy. Arch Sex Behav 1983;12:59–62
  • Batra AK, Lue TF. Penile erection: circulatory physiology. In Kirby RS, Carson C, Webster GD, eds. Impotence:  Diagnosis and Management of Male Erectile Dysfunction. Oxford: Butterworth-Heinemann, 1991:19–26
  • Bookstein JJ, Valji K, Parsons L, Kessler W. Pharmacoarteriography in the evaluation of impotence. J Urol 1987;137:333–7
  • Boolel M, Allen MJ, Ballard SA, et al. An orally active type 5 cyclic GMP phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 1996;8:47–52
  • Boolel M, Gepi-Attee S, Gingell JC, Allen MJ. Sildenafil, a novel effective oral therapy for male erectile dysfunction. Br J Urol 1996;78: 257–61
  • Boulton AJM, Selam J-L, Sweeney M, Ziegler D. Sildenafil citrate for the treatment of erectile dysfunction in men with type II diabetes mellitus. Diabetologia 2001;44:1296–301
  • Brindley GS. Cavernosal alpha-blockade: a new technique for investigating and treating erectile impotence. Br J Psychiatr 1983;143:332–7
  • Brock G. Oral agents: first-line therapy for erectile dysfunction. Eur Urol 2002;(Suppl) 1:12–18
  • Brock GB, MacMahon CG, Chen KK, et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses.  J Urol2002; 168:1332–6
  • Brock GB, Taylor T, Seger M, and the Vardenafil PROSPECT Group. Efficacy and tolerability of vardenafil in men with erectile dysfunction following radical prostatectomy. Eur Urol 2002(Suppl 1):152
  • Burnett AL. Role of nitric oxide in the physiology of erection. Biol Reprod 1995;52:485–9
  • Burnett AL, Hillman SL, Chang TSK, et al. Immunohistochemical localization of nitric oxide synthase in the autonomic innervation of the human penis. J Urol 1993;150:73–6
  • Buvat JS, Gingell CJ, Jardin A, et al. Sildenafil (Viagra), an oral treatment for erectile dysfunction: A 1-year open-label extension study. J Urol 1997;157(Suppl):204
  • Carson CC, Burnett AL, Levine LA, Nehra A. The efficacy of sildenafil citrate [Viagra] in clinical populations. Urology 2002;60:12–27
  • Cavallini G. Minoxidil versus nitroglycerin: a prospective double-blind controlled trial in transcutaneous erection facilitation for organic impotence. J Urol 1991; 146:50–3 Chen K, Chan SHH, Chang LS, Chan
  • JYH. Participation of paraventricular nucleus of the hypothalamus in central regulation of penile erection in the rat. J Urol 1997;158:238–44
  • Dinsmore WW, Alderdice DK. Vasoactive intestinal polypeptide and phentolamine mesylate administered by autoinjector in the treatments of patients with erectile dysfunction resistant to other intracavernosal agents. Br J Urol 1998;81:437–40
  • Eardley I, Kirby RS, Fowler CJ. Neurophysiological testing. In Kirby RS, Carson C, Webster GD, eds. Impotence: Diagnosis and Management of Male Erectile Dysfunction. Oxford: Butterworth-Heinemann, 1991:109–16
  • FDA Sildenafil Summary Basis of Approval, Study 148–227
  • Feldman HA, Goldstein I, Hatzichrisou DG, et al. Impotence and its medical and psychological correlates: Results of the Massachusetts Male Aging Study. J Urol 1994;151:54–61
  • Finasteride Study Group. Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Prostate 1993;22:291–9
  • Furchgott RF, Zawadski JV. The obligatory role of endothelial cell in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980;288:373–8
  • Furlow WL. Prevalence of impotence in the United States. Med Aspects Hum Sex 1985; 19:13–16
  • Furlow WL, Goldwasser B, Gundian JC. Implantation of model AMS700 penile prosthesis: Long-term results. J Urol 1988;139:741–2
  • Godschalk MF, Chen J, Katz PG, Mulligan T. Treatment for erectile failure with prostaglandin El: a double-blind, placebo-controlled, dose-response study. J Urol 1998; 151:1530–2
  • Goldstein I, Lue TF, Padma-Nathan H, et al. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998 ;338:1397–404
  • Goldstein I, Young M, Fischer J, et al. Vardenafil, a new highly selective PDE5 inhibitor, improves erectile function in patients with diabetes mellitus. Diabetes 2001;50 (Suppl2):114
  • Guiliano F. Phosphodiesterase type 5 inhibition in erectile dysfunction: an overview. Eur Heart J 2002;(Suppl H):H7–12
  • Hai CM, Murphy RA. Crossbridge phosphorylation and regulation of the latch state in smooth muscle. Am J Physiol 1988;255:86–94
  • Heaton JPW. Key issues from the clinical trials of apomorphine SL. World J Urol 2001; 19:25–31
  • Heaton JPW, Morales A, Owen J. Topical glyceryltrinitrate causes measurable penile arterial dilatation in impotent men. J Urol 1990; 143: 729–31
  • Heaton JPW, Morales A, Adams MA, Johnson B. Recovery of erectile function by the oral administration of apomorphine. Urology 1995; 45:200–6
  • Hellstrom WJF, Gittelman M, Karlin G, et al Vardenafil for treatment of men with erectile dysfunction. Efficacy and safety in a randomized, double-blind, placebocontrolled trial. J Androl 2002;23:763–71
  • Hermann HC, Chang G, Klugherz BD, Mahoney PD. Hemodynamic effects of sildenafil in men with severe coronary artery disease. N Engl J Med 2000;342:1622–6
  • Hong EK, Lepor H, McCullough AR. Time dependent patient satisfaction with sildenafil for erectile dysfunction (ED) after nerve-sparing radical retropubic prostatectomy. Int J Impot Res 1999;11:S15–22
  • Kim ED, McVary K. Topical prostaglandin E1 for the treatment of erectile dysfunction. J Urol 1995;153:1828–30
  • Kirby RS. Impotence: diagnosis and management of male erectile dysfunction. Br Med J 1994;308:957–61
  • Krane RJ, Goldstein I, Saenz de Tejada I. Impotence. N Engl J Med 1989;321:1648–59
  • Lerner SE, Melman A, Christ GJ. Review of erectile dysfunction: new insights and more questions. J Urol 1993;149:1246–55
  • Levin RM, Wein AJ. Adrenergic alpha receptors outnumber beta receptors in human penile corpus cavernosum. Invest Urol 1980; 18: 225–6
  • Lue TF. Impotence after radical pelvic surgery: physiology and management. Urol Int 1991;46:259–63
  • Lue TF, Hricak H, Marich KW, Tanagho EA. Vasculogenic impotence evaluated by high-resolution ultrasonography and pulsed Doppler spectrum analysis. Radiology 1985;155:777–81
  • Lue TF, Tanagho EA. Physiology of erection and pharmacological management of impotence. J Urol 1987;137:829–36
  • McConnell JD, Bruskewitz R, Walsh PC, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 1998;338:557–63
  • McCulloch DK, Campbell IW, Wu FC, et al. The prevalence of diabetic impotence. Diabetologia 1980; 18:279–83
  • McCullough AR, Barada JH, Fawzy A; et al. Achieving treatment optimization with sildenafil citrate (Viagra) in patients with erectile dysfunction. Urology 2002;60:28–38
  • McMahon CG, Samali R, Johnson H. Efficacy, safety and patient acceptance of sildenafil as treatment for erectile dysfunction. J Urol 2000; 164:1192–6
  • Michael V. Arterial disease as a cause of impotence. Clin Endocrinol Metab 1982;11:725–48
  • Mirone VG, Steif CG. Efficacy of apomorphone SL in erectile dysfunction. BJU Int 2001;88(Suppl 3):25–9
  • Morales A, Condra M, Owen JA, et al. Is yohimbine effective in the treatment of organic impotence? Results of a controlled trial. J Urol 1987;137:1168–72
  • Moreira SG, Brannigan RE, Spitz A, et al. Side-effect profile of sildenafil citrate (Viagra) in clinical practice. Urology 2000;56:474–6
  • Naylor AM. Endogenous neurotransmitters mediating penile erection. Br J Urol 1998;81:424–31
  • Nesbit RM. Congenital curvature of the phallus: a report of three cases with a description of the corrective operation. J Urol 1965;93:230–4
  • Neaton JD, Grimm J, Prineas RJ, et al. and the Treatment for Mild Hypertension Study Group. Treatment of Mild Hypertension Study. Final results. J Am Med Assoc 1993;270:713–24
  • Nicolosi A, Moreira ED, Shiai M, et al. Epidemiology of erectile dysfunction in four countries: cross-national study of the prevalence and correlates of erectile dysfunction. Urology 2003;61:201–6
  • O’Leary MP, Fowler FJ, Lenderking WR, et al. A brief male sexual function inventory for urology. Urology 1995;5:46–9
  • Padma-Nathan H, Eardley I, Kloner RA, et al. A 4-year update on the safety of sildenafil citrate (Viagra). Urology 2002;60:67–90
  • Padma-Nathan H, Goldstein I, Payton T, Krane RJ. Intracavernosal pharmacotherapy: the pharmacologic erection program. World J Urol 1987;5:160–5
  • Padma-Nathan H, Hellstrom WJ, Kaiser FF, et al. and the MUSE Study Group. Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated urethral system for erection (MUSE). N Engl J Med 1997;336:l–7
  • Padma-Nathan H, McMurray JG, Pullman WE, et al. Ondemand IC351 (Cialis ™) enhances erectile function in patients with erectile dysfunction. Int J Impot Res 2001;13:2–9
  • Padma-Nathan H, Stecher VJ, Sweeney M, et al. Minimal time to successful intercourse after sildenafil citrate: results of a randomized, double-blind, placebo-controlled trial. Urology 2003;62:400–3
  • Palmer LS, Valcic M, Melman A, et al. Characterization of cyclic AMP accumulation in cultured human corpus cavernosum smooth muscle cells. J Urol 1994;152:1308–14
  • Patel U, Amin Z, Friedman E, et al. Colour flow and spectral Doppler imaging after papaverine-induced erection in 220 impotent men:study of temporal patterns and the importance of repeated sampling, velocity asymmetry and vascular anomalies. Clin Radiol 1993;48: 18–24
  • Raina R, Lakin MM, Agarwal A, et al. Long-term effect of sildenafil citrate on erectile dysfunction after radical prostatectomy: 3-year follow-up. Urology 2003;62;110–15
  • Rajfer J, Aronson WJ, Bush PA, et al. Nitric oxide as a mediator of relaxation of the corpora cavernosa in response to non-adrenergic, non-cholinergic neurotransmission. N Engl J Med 1992;3:90–4
  • Reid K, Morales A, Harris C, et al. Double-blind trial of yohimbine in treatment of psychogenic impotence. Lancet 1987;ii:421–3
  • Rendell MS, Rajfer J, Wicker PA, Smith MD. Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group. J Am Med Assoc 1999;281:421–6
  • Rosen R, Riley A, Wagner G, et al. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997;49:822–30
  • Ruffolo RR, Nichols AJ, Stadel JM, Hieble JP. Structure and function of alpha-adrenoceptors. Pharm Rev 1991;43:475–505
  • Saenz de Tejada I, Knight JR, Anglin G, Emmick JT. Effects of tadalafil on erectile dysfunction in men with diabetes. Diabetes Care 2002; 25:2159–64
  • Saenz de Tejada I, Angulo J, Cuevas P, et al. The phosphodiesterase inhibitory selectivity and the in vivo potency of the new PDE 5 inhibitor vardenafil. Int J Impot Res 2001;13:284–90
  • Stackl W, Hasun R, Marberger M. Intracavernous injection of prostaglandin El in impotent men. J Urol 1988;140:66–8
  • Steers W, Guay AT, Leriche A, et al. Assessment of the efficacy and safety of Viagra (sildenafil citrate) in men with erectile dysfunction during long-term treatment. Int J Impot Res 2001; 13:261–7
  • Stuckey BGA, Jadzinsky MN, Murphy LJ, et al. Sildenafil citrate for treatment of erectile dysfunction in men with type 1 diabetes. Results of a randomized controlled trial. Diabetes Care 2003;26:279–84
  • Susset JG, Tessier CD, Wincze J, et al. Effect of yohimbine hydrochloride on erectile impotence: a double-blind study. J Urol 1989; 141: 1360–3
  • TOMHS Research Group. Incidence and disappearance of erectile problems in men treated for stage I hypertension: The Treatment of Mild Hypertension Study (TOMHS). Eur Urol 1996;30(Suppl):38–42
  • Viagra US Package Insert
  • Virag R, Bouilly P, Frydman D. Is impotence an arterial disorder? A study of arterial risk factors in 440 impotent men. Lancef 1985;i: 181–4
  • Virag R, Shoukry K, Floresco J, et al. Intracavernous selfinjection of vasoactive drugs in the treatment of impotence. J Urol 1991;145: 287–93
  • Wagner TH, Patrick DL, McKenna SP, Froese PS. Crosscultural development of a quality of life measure for men with erection difficulties. Qual Life Res 1996;5:443–9
  • Wespes E, Schulman CC. Venous leakage: surgical treatment of a curable cause of impotence. J Urol 1985; 133:796–8
  • Wespes E, Schulman C. Venous impotence: pathophysiology, diagnosis and treatment. J Urol 1993;149:1238–45
  • Wilson SK, Wahman GE, Lange JL. Eleven years’ experience with the inflatable penile prosthesis. J Urol 1988;139:951–2
  • Witherington R. Vacuum constriction device for management of erectile impotence. J Urol 1989;141:320–2
  • Zelefsky MJ, McKee AB, Lee H, Leibel SA. Efficacy of oral sildenafil in patients with erectile dysfunction after radiotherapy for carcinoma of the prostate. Urology 1999;53:775–8
  • Zippe CD, Jhaveri FM, Klein EA, et al. Role of Viagra after radical prostatectomy. Urology 2000;55:241–5

Provided by ArmMed Media